

PERSONAL INFORMATION



Lorenzo Tofani

 Viale degli Eroi di Rodi, 87 00128 Rome (Italy)

 +39 3317973661

 lorenzotofani1993@gmail.com

 lorenzotofani@omceoromapec.it

Sex Male | Date of birth 18/01/1993 | Nationality Italian

PERSONAL STATEMENT

Medical Doctor in Dermatology and Venereology

WORK EXPERIENCE

Sep 2024 –Today (Sep 2026)

Research Grant – University of Rome “Tor Vergata”, Department of Internal Medicine
Research Program Title: “The ocular involvement in patients affected by atopic dermatitis: the correct management of atopic patient”

Dec 2023 – Aug 2024

Istituto Dermopatico dell’Immacolata I.R.C.C.S, Fondazione Luigi Maria Monti

EDUCATION

Sep 2012 – Jul 2018

Single cycle degree course in medicine and surgery
 University of Rome “Tor Vergata”
Thesis Title: “Polipi Endometriali In Età Riproduttiva e in Premenopausa: Ruolo Della Polipectomia Resettoscopica”

Nov 2018 - Mar 2019

Qualification to practice the profession of doctor in medicine and surgery
 University of Rome “Tor Vergata”

Mar 2019 – Sep 2019

Specific training in general medical practice (19° CFSMG REGIONE LAZIO)
 ASL Rome 2 Lazio Region

Nov 2019 – Nov 2023

Resident physician in Dermatology and Venereology
 University of Rome “Tor Vergata”
Thesis Title: “Cheratocongiuntivite Atopica (AKC) Nei Pazienti Affetti Da Dermatite Atopica Trattati Con Dupilumab O Upadacitinib”

TRAINING

Oct 2019

Auditor- Farmaci biotecnologici e biosimilari: esperienze real-life in dermatologia

Nov 2019

Sponsored event participant- PSOspective: Ixekizumab, prospettive di efficacia

Dec 2019	Auditor- Scuola Dermatologica Sergio Chimenti
Dec 2019	Auditor- Sidemast regionale del Lazio
Feb 2020	Sponsored event participant- Complete Action
Jun 2020	Field Medical Training Participant Speaker- "Advisory Board in Dermatologia" Place in therapy di brodalumab: tra sostenibilità, opzioni terapeutiche ed appropriatezza <i>Casistica clinica universitaria e non Lazio</i>
Nov 2020	Docent- Tutorial Malattie Infiammatorie Croniche della Cute: DA <i>Practise Module</i>
Jul 2021	Online Auditor- Scuola Dermatologica Sergio Chimenti
Jul 2021	Online Auditor- Inibitori dell'interleuchina 17 nella Psoriasi: dai Trial Clinici all'esperienza Real-Life
Oct 2021	Online Relator- 95° SIDeMaST <i>Efficacia e sicurezza di brodalumab nell'eritrodermia psoriasica</i>
Oct 2021	Auditor- Dermoscopia e tumori cutanei
Oct 2021	Online Auditor- Tutorial Malattie Infiammatorie Croniche della Cute: Psoriasi
Dec 2021	Online Auditor- Scuola Dermatologica Sergio Chimenti
Dec 2021	Online Auditor- Inibitori dell'interleuchina 23 nella Psoriasi: dai Trial Clinici all'esperienza Real-Life
Dec 2021	Online Auditor- Tutorial Malattie Infiammatorie Croniche della Cute: DA ed HS
May 2022	Auditor- Medical writing in dermatologia
Jun 2022	Relator- Scuola Dermatologica Sergio Chimenti <i>Pazienti obesi failure a terapie con anti interleuchina 23 responsivi a terapia con brodalumab: un case series</i>
Sep 2022	Non member physician - European Academy of Dermatology and Venereology Congress
Dec 2022	Relator- Scuola Dermatologica Sergio Chimenti <i>Il mio caso piu' interessante di psoriasi trattato con: brodalumab</i>
Dec 2022	Docent- Tutorial Malattie Infiammatorie Croniche della Cute: DA <i>Practise Module</i>
Dec 2022	Field Medical Training Participant- "Percorso di co-creazione per il miglioramento della gestione del paziente affetto da dermatite atopica"
Mar 2023	Auditor- Psoriasi senza frontiere
Mar 2023	Non member physician- American Academy of Dermatology and Venereology Congress
Sep 2023	Relator- VIII Congresso Scuola della Psoriasi <i>Medicina di precisione nella psoriasi: predizione della risposta al trattamento con farmaci biologici tramite l'analisi di varianti alleliche predisponenti alla malattia</i>
Oct 2023	Non member physician - European Academy of Dermatology and Venereology Congress
Nov 2023	Auditor – SIDeMaST Winter Symposium
Nov 2023	Field Medical Training Participant Speaker – Occhio Alla Dermatite: il coinvolgimento oculare nei pazienti affetti da dermatite atopica <i>Manifestazioni oculari in pazienti con dermatite atopica</i>

Apr 2024

Auditor – 15th SKIN ACADEMY - Barcelona

AWARDS

- Dec 2023 **New Skin Real World – Dalla Teoria alla Pratica 2023**
1st classification
Project Title: Tildrakizumab in sedi difficili da trattare: scalpo, unghie, palmo-plantare e sedi genitali. Drug survival in due popolazioni di pazienti, di cui una trattata con 100mg e l'altra con 200mg.
- Jul 2024 **Journal of Clinical Medicine 2024 Best Paper Award**
Winner Paper: Efficacy of Tildrakizumab for the Treatment of Difficult-to-Treat Areas: Scalp, Nail, Palmoplantar and Genital Psoriasis

CLINICAL TRIALS

- Jun 2020 - Oct 2023 **Sponsor Protocol Name: Study I4V-MC-JAHN**
Start Date: 2017-10-27
EudraCT Number: 2017-000873-35
Full Title: A Phase 3 Multicenter, Double-Blind Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Adult Patients with Atopic Dermatitis
Sub-Investigator
Site: ITA127
- Jun 2020 - Oct 2023 **Sponsor Protocol Name: Study I4V-MC-JAIN**
Start Date: 2018-04-05
EudraCT Number: 2017-004574-34
Full Title: A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Safety and Efficacy of Baricitinib in Combination with Topical Corticosteroids in Adult Patients with Moderate-to-Severe Atopic Dermatitis Who Have Experienced Failure to Cyclosporine or Are Intolerant to, or Have Contraindication to, Cyclosporine
Sub-Investigator
Site: ITA221
- Jun 2020 - Oct 2022 **Sponsor Protocol Name: I6T-MC-AMAH**
Start date: 2018-09-03
EudraCT Number: 2017-003299-30
Full Title: A Multicenter, Long-Term Extension to Evaluate the Long-Term Safety and Maintenance of Treatment Effect of Mirikizumab in Patients with Moderate-to-Severe Plaque Psoriasis (OASIS-3)
Sub-Investigator
Site: ITA650
- Sep 2020 – Sep 2022 **Sponsor Protocol Name: COBRA LP0160-1510**
Start date: 2021-05-24
EudraCT Number: 2019-004099-20
Full Title: Efficacy and safety comparison of brodalumab versus guselkumab in adult subjects with moderate-to-severe plaque psoriasis and inadequate response to ustekinumab
UNblinded Sub-Investigator
Site: ITALY1488

PERSONAL SKILLS

Mother tongue(s)
Other language(s)

Italian	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken interaction	Spoken production	
English	B1	B1	B1	B1	B1
Preliminary English Test (B1 level). Date of Issue: 05/07/2010					

Digital skills

SELF-ASSESSMENT				
Information processing	Communication	Content creation	Safety	Problem solving
Independent user	Independent user	Independent user	Independent user	Independent user

Other skills Lifeguard's license: beach, inland open waters and pool categories

Driving licence A1, B

Publications

1. Galluzzo M, Tofani L, Bianchi L, Talamonti M. Status of a real-life cohort of patients with moderate-to-severe plaque psoriasis treated with secukinumab and considerations on the use of biological agents in the Covid-19 era. *Expert Opin Biol Ther.* 2020 Aug;20(8):829-830. doi: 10.1080/14712598.2020.1779217. Epub 2020 Jun 16. PMID: 32510244.
2. Galluzzo M, Tofani L, Lombardo P, Petruzzellis A, Silvaggio D, Egan CG, Bianchi L, Talamonti M. Use of Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A 1 Year Real-Life Study. *J Clin Med.* 2020 Jul 9;9(7):2170. doi: 10.3390/jcm9072170. PMID: 32659978; PMCID: PMC7408922.
3. Talamonti M, Tofani L, Bianchi L, Galluzzo M. Optimizing care for psoriatic patients requiring systemic therapies: how will COVID-19 disease transform risk perceptions? *Arch Dermatol Res.* 2021 Mar;313(2):127-128. doi: 10.1007/s00403-020-02103-z. Epub 2020 Jul 9. PMID: 32647977; PMCID: PMC7344026.
4. Di Raimondo C, Rao L, Lozzi F, Lombardo P, Silvaggio D, Vellucci L, Tofani L, Campione E, Bianchi L. Cemiplimab and ruxolitinib in concomitant cutaneous squamous cell carcinoma and myelofibrosis. *Dermatol Ther.* 2022 May;35(5):e15421. doi: 10.1111/dth.15421. Epub 2022 Mar 12. PMID: 35249252.
5. Galluzzo M, Talamonti M, Cioni A, Maffei V, Shumak RG, Tofani L, Bianchi L, Campione E. Efficacy of Tildrakizumab for the Treatment of Difficult-to-Treat Areas: Scalp, Nail, Palmoplantar and Genital Psoriasis. *J Clin Med.* 2022 May 7;11(9):2631. doi: 10.3390/jcm11092631. PMID: 35566756; PMCID: PMC9100809.
6. Caldarola G, Galluzzo M, Bernardini N, Calabrese L, Grimaldi M, Moretta G, Pagnanelli G, Shumak RG, Talamonti M, Tofani L, Pallotta S, Peris K, Potenza C, De Simone C, Campione E. Tildrakizumab in moderate-to-severe plaque psoriasis: A multicenter, retrospective, real-life study. *Dermatol Ther.* 2022 Jun;35(6):e15488. doi: 10.1111/dth.15488. Epub 2022 Apr 11. PMID: 35384168; PMCID: PMC9287013.
7. Galluzzo M, Marcelli L, Vellucci L, Paganini C, Maffei V, Tofani L, Belcastro A, Bianchi L, Talamonti M. Guselkumab for treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and drug-survival for up to 148 weeks. *Expert Opin Biol Ther.* 2023 Apr;23(4):371-381. doi: 10.1080/14712598.2023.2194485. Epub 2023 Mar 27. PMID: 36971507.
8. Campione E, Lambiase S, Gaeta Shumak R, Galluzzo M, Lanna C, Costanza G, Borselli C, Artosi F, Cosio T, Tofani L, Dattola A, Di Daniele F, Bianchi L. A Real-Life Study on the Use of Tildrakizumab in Psoriatic Patients. *Pharmaceuticals (Basel).* 2023 Mar 31;16(4):526. doi: 10.3390/ph16040526. PMID: 37111283; PMCID: PMC10141711.
9. Galluzzo M, Tofani L, Spelta S, Talamonti M, Micera A, Bianchi L, Coassin M, Bonini S, Di Zazzo A. Dupilumab-associated ocular surface disease or atopic keratoconjunctivitis not improved by dupilumab? Upadacitinib may clarify the dilemma: A case report. *Skin Health Dis.* 2024 Mar 15;4(3):e354. doi: 10.1002/ski2.354. PMID: 38846697; PMCID: PMC11150752.
10. Paganini C, Spelta S, Tofani L, Talamonti M, Bianchi L, Coassin M, Di Zazzo A, Galluzzo M. Impact of Upadacitinib on Atopic Keratoconjunctivitis Exacerbated by Dupilumab Treatment in Atopic Dermatitis Patients: A Prospective Dermatological and Ophthalmological Clinical Evaluation in Common Clinical Practice. *J Clin Med.* 2024; 13(13). doi: 10.3390/jcm13133818

Personal data

I authorize the processing of my data under the Legislative Decree 30 June 2003, Nm. 196 "Code on the Protection of Personal Data".